Read the findings & sources
Human study discussedA 26-week phase II trial in adults with overweight or obesity without diabetes reported mean weight reductions from 6.0% to 10.8% across cagrilintide groups, versus 3.0% with placebo in its trial-product analysis. Gastrointestinal symptoms, including nausea, were frequent. This supports study of amylin signaling in weight regulation, while leaving long-term outcomes and formulation-specific safety as separate questions.